Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
819
datasets available to search
ShareScore release 0.9.0
Dataset results
819 results for “Brain Tumor”
Microarray of Mouse Brain Tumors grown from injections of GL26 cell line
GEO Series GSE11420. Mus musculus. 15 samples. Type: Expression profiling by array.
Age-related gene signatures in brain tumors of young and old mice
GEO Series GSE135062. Mus musculus. 6 samples. Type: Expression profiling by high throughput sequencing.
Gene Expression data from human brain tumor or normal brain
GEO Series GSE30563. Homo sapiens. 6 samples. Type: Expression profiling by array.
Brain Tumor Registry of Japan (2001-2004)
In 1975, the Brain Tumor Registry of Japan (BTRJ) was founded to investigate the statistical characteristics of brain tumors in Japan. The Committee of the BTRJ has published 12 reports. The 12th report of the BTRJ, which includes 82,844 primary and metastatic brain tumor cases from 1984 to 2000, was issued in 2009. Here, we publish the 13th edition of the BTRJ. This edition contains the statistical data of 16,338 patients in Japan with primary and metastatic brain tumors from 2001 to 2004. The numbers reported below are for patients under the age of 40 years old.
Delineating pediatric brain tumor progression using single-nuclei sequencing
For more information, including a more complete description, data generator contact information, and reference, please see: https://scpca.alexslemonade.org/projects/SCPCP000010.
Exploring the Microbiome-Gut-Brain Axis with Respect to Psychoneurological Symptoms for Children with Solid Tumors
The human body hosts tens of trillions of microbes, a number 10 times greater than the number of human body cells. The collection of these human-associated microbes and their genomes is called the "human microbiome". More than 90% of these microbes live in the gastrointestinal (GI) tract, representing 500 species on average. With the development of high-throughput sequencing technology and bioinformatics tools (e.g., 16S ribosomal RNA or 16S rRNA sequencing and shotgun metagenomics analysis), recent progress has been made to elaborate the critical role that the gut microbiome plays in human health and disease. A significant disruption (dysbiosis) of the composition and function of the gut microbiome is associated with carcinogenesis, chemotherapeutic metabolism, and treatment-related symptom toxicities. The current state of science on the gut microbiome in cancer has only recently started in animal models and adults, and has not been well investigated in children diagnosed and treated for cancer, nor with respect to associations with cancer treatment-related toxicities. This proposed study will explore the hypothesis that dysbiosis of the gut microbiome is associated with cancer treatment-related GI and psychoneurological symptoms. We will collect both stool samples (for the gut microbiome) and patient-reported outcomes across chemotherapy.
Molecular Characterization across Pediatric Brain Tumors and Other Solid and Hematologic Malignancies for Research, Diagnostic, and Precision Medicine
This study contains tumor and germline WGS, RNA-Seq, Clinical Panel Sequencing, and other omics and molecular data for patients with pediatric brain tumors and other solid and hematologic malignancies. This data has been collected from multiple organizations including the multi-institute Children's Brain Tumor Network (CBTN), the Pacific Pediatric Neuro-Oncology Consortium (PNOC), and the Children's Hospital of Philadelphia Division for Genomic Diagnostics (CHOP DGD). In addition to being available pre-publication and without embargo via dbGaP and the NCI Cancer Research Data Commons, this data is made available via Cavatica, PedcBioPortal and the Kids First Data Resource Portal. Collectively, this availability strives to accelerate the research process and enable members of the scientific and patient communities to partner and make discoveries faster than ever before. In 2019, the CBTN launched the Pediatric Brain Tumor Atlas, which now comprises the largest collection of childhood brain tumor data in the world. This resource is helping accelerate not only brain tumor research, but is also empowering discovery for other rare childhood conditions. Brain tumors are the most common form of cancer in children aged 0-19 in the United States, and are the largest cause of cancer-related deaths. The estimated number of new cases in 2019 is nearly 3,800, and thus brain tumors are a rare disease. Despite their relative rarity, the years of potential life lost due to brain tumors in 2009 was estimated at 47,631 years for children and adolescents aged 0-19 in the United States; this is a disproportionate amount of life lost compared to adult cancers and represents an unrecognized societal threat. There is an urgent need to improve therapies for these children. This sequencing cohort defines the largest, clinically annotated pediatric brain tumor cohort study to date and seeks to define the intersection of germline and somatic underpinnings of pediatric brain tumors across a shared developmental context of cancer and structural birth defects.
Dataset related to article "Surgery Followed by Hypofractionated Radiosurgery on the Tumor Bed in Oligometastatic Patients With Large Brain Metastases. Results of a Phase 2 Study"
<p>PURPOSE:</p> <p>This prospective phase II study assessed safety and feasibility of surgery followed by hypofractionated radiosurgery (HSRS) on the tumor bed in oligometastatic patients with single large brain metastases (BMs).</p> <p>METHODS AND MATERIALS:</p> <p>Between June 2015 and May 2018, 101 patients were enrolled. Oligometastatic disease was defined by a maximum of 5 extracranial metastatic lesions. HSRS was performed within 1 month of surgery and consisted of 30 Gy in 3 fractions. Local control, occurrence of new BMs, overall survival, and treatment-related toxicities were assessed.</p> <p>RESULTS:</p> <p>At a median follow-up time of 26 months, local recurrence occurred in 6 patients (5.9%). Six-month, 1-year, and 2-year local control rates were 100%, 98.9% ± 1.1%, and 85.9% ± 0.6%, respectively. New BMs occurred in 39 patients (38.6%); median brain distant progression time and 6-month, 1-year, and 2-year brain distant progression rates were 39 months (95% CI, 19-39 months), 17% ± 3.7%, 31.4% ± 4.8%, and 42.5% ± 5.9%, respectively. At the last observation time, 50 patients (49.5%) were alive and 51 (50.5%) were dead; 10 patients died owing to neurologic causes and 40 as a result of systemic progression. Median overall survival time and 6-month, 1-year, and 2-year overall survival rates were 22 months (95% CI, 20-30 months), 95% ± 2.1%, 81.9% ± 3.8%, and 46.6% ± 6%, respectively. Infratentorial site, residual tumor volume, longer interval time between primary diagnosis and occurrence of BMs, and oligometastatic disease status significantly influenced outcome. Grade 2 to 3 radionecrosis occurred in 26 patients. Neurocognitive functions remained stable or, in some cases, improved.</p> <p>CONCLUSIONS:</p> <p>Surgery followed by HSRS on the tumor bed is a safe and effective approach, affording good brain control with acceptable toxicities. As for extracranial metastatic sites, patients with BMs can benefit from local ablative treatment in the context of an oligometastatic disease.</p>
DATASET RELATED TO ARTICLE "Preoperative nonmedical predictors of functional impairment after brain tumor surgery"
<p>The .xls datasheet contains anonymized demographic, clinical e neuropsychological evaluation data of patients involved in the study reported at title.</p> <p>Variables list: </p> <table> <tbody> <tr> <td>gender</td> </tr> <tr> <td>age</td> </tr> <tr> <td>Tumor location</td> </tr> <tr> <td>Location groups</td> </tr> <tr> <td>Eloquent area</td> </tr> <tr> <td>Tumor side</td> </tr> <tr> <td>Dimension</td> </tr> <tr> <td>KPS preoperatory</td> </tr> <tr> <td>complication</td> </tr> <tr> <td>Landriel classification</td> </tr> <tr> <td>KPS discharge</td> </tr> <tr> <td>Histology</td> </tr> <tr> <td>diagnosis</td> </tr> <tr> <td>WHO grade</td> </tr> <tr> <td>KPS follow up</td> </tr> <tr> <td>T0 Datacompilazione</td> </tr> <tr> <td>educational level</td> </tr> <tr> <td>YEARS STUDY</td> </tr> <tr> <td>MARITAL STATUS</td> </tr> <tr> <td>living situation</td> </tr> <tr> <td>T0 Personenucleofamiliare</td> </tr> <tr> <td>WORK</td> </tr> <tr> <td>T0 WHODAS12 Totalscore</td> </tr> <tr> <td>T0 WHODAS12 H1</td> </tr> <tr> <td>T0 WHODAS12 H2</td> </tr> <tr> <td>T0 WHODAS12 H3</td> </tr> <tr> <td>T0 WHODAS12 H4</td> </tr> <tr> <td>T0 WHODAS12 H5</td> </tr> <tr> <td>T0 HADS anxiety</td> </tr> <tr> <td>T0 HADS depression</td> </tr> <tr> <td>T0 HADS emotional distress</td> </tr> <tr> <td>T0 OSLO</td> </tr> <tr> <td>T0 TIPIEXTRAVERSION</td> </tr> <tr> <td>T0 TIPIAGREEABLENESS</td> </tr> <tr> <td>TO TIPICOSCIENZIOUSNESS</td> </tr> <tr> <td>TO TIPINEUROTICISM</td> </tr> <tr> <td>T0 TIPIOPENESS</td> </tr> <tr> <td>T0 RS14</td> </tr> <tr> <td>T0 RS14 Livello</td> </tr> <tr> <td>T0 EORTC global health</td> </tr> <tr> <td>T0 EORTC physical functioning</td> </tr> <tr> <td>T0 EORTC role functioning</td> </tr> <tr> <td>T0 EORTC emotional functioning</td> </tr> <tr> <td>T0 EORTC cognitive functioning</td> </tr> <tr> <td>T0 EORTC social functioning</td> </tr> <tr> <td>T0 EORTC fatigue</td> </tr> <tr> <td>T0 EORTC NV</td> </tr> <tr> <td>T0 EORTC PA</td> </tr> <tr> <td>T0 EORTC DY</td> </tr> <tr> <td>T0 EORTC SL</td> </tr> <tr> <td>T0 EORTC AP</td> </tr> <tr> <td>T0 EORTC CO</td> </tr> <tr> <td>T0 EORTC DI</td> </tr> <tr> <td>T0 EORTC FI</td> </tr> <tr> <td>T0 BN20 BNFU</td> </tr> <tr> <td>T0 BN20 BNVD</td> </tr> <tr> <td>T0 BN20 BNMD</td> </tr> <tr> <td>T0 BN20 BNCD</td> </tr> <tr> <td>T0 BN20 BNHA</td> </tr> <tr> <td>T0 BN20 BNSE</td> </tr> <tr> <td>T0 BN20 BNDR</td> </tr> <tr> <td>T0 BN20 BNIS</td> </tr> <tr> <td>T0 BN20 BNHL</td> </tr> <tr> <td>T0 BN20 BNWL</td> </tr> <tr> <td>T0 BN20 BNBC</td> </tr> <tr> <td>T0 FAS raw score</td> </tr> <tr> <td>T0 FAS standard score</td> </tr> <tr> <td>T0 FAS equivalent scores</td> </tr> <tr> <td>T0 ROWL IR raw score</td> </tr> <tr> <td>T0 ROWL IR standard score</td> </tr> <tr> <td>T0 ROWL IR equivalent score</td> </tr> <tr> <td>T0 ROWL DR raw score</td> </tr> <tr> <td>T0 ROWL DR standard score</td> </tr> <tr> <td>T0 ROWL DR equivalent score</td> </tr> <tr> <td>T0 TMTA raw score</td> </tr> <tr> <td>T0 TMTA standard score</td> </tr> <tr> <td>T0 TMTA equivalent score</td> </tr> <tr> <td>T0 TMTB raw score</td> </tr> <tr> <td>T0 TMTB standard score</td> </tr> <tr> <td>T0 TMTB equivalent score</td> </tr> <tr> <td>T0 TMTBA PG</td> </tr> <tr> <td>T0 TMTBA PC</td> </tr> <tr> <td>T0 TMTBA PE</td> </tr> <tr> <td>T0 MOCATOT raw score</td> </tr> <tr> <td>T0 MOCATOT standard score</td> </tr> <tr> <td>T0 MOCATOT equivalent score</td> </tr> <tr> <td>T0 MOCAVisuospatial PG</td> </tr> <tr> <td>T0 MOCAExecutive PG</td> </tr> <tr> <td>T0 MOCALanguage PG</td> </tr> <tr> <td>T0 MOCAOrientation PG</td> </tr> <tr> <td>T0 MOCAAttention PG</td> </tr> <tr> <td>T0 MOCAMemory PG</td> </tr> <tr> <td>T0 MOCAVisuospatial PC</td> </tr> <tr> <td>T0 MOCAExecutive PC</td> </tr> <tr> <td>T0 MOCALanguage PC</td> </tr> <tr> <td>T0 MOCAOrientation PC</td> </tr> <tr> <td>T0 MOCAAttention PC</td> </tr> <tr> <td>T0 MOCAMemory PC</td> </tr> <tr> <td>T0 MOCAVisuospatial PE</td> </tr> <tr> <td>T0 MOCAExecutive PE</td> </tr> <tr> <td>T0 MOCALanguage PE</td> </tr> <tr> <td>T0 MOCAOrientation PE</td> </tr> <tr> <td>T0 MOCAAttention PE</td> </tr> <tr> <td>T0 MOCAMemory PE</td> </tr> <tr> <td>FU Datacompilazione</td> </tr> <tr> <td>FU WHODAS12 Totalscore</td> </tr> <tr> <td>FU WHODAS12 H1</td> </tr> <tr> <td>FU WHODAS12 H2</td> </tr> <tr> <td>FU WHODAS12 H3</td> </tr> <tr> <td>FU WHODAS12 H4</td> </tr> <tr> <td>FU WHODAS12 H5</td> </tr> <tr> <td>FU HADS anxiety</td> </tr> <tr> <td>FU HADS depression</td> </tr> <tr> <td>FU HADS emotional distress</td> </tr> <tr> <td>FU EORTC global health</td> </tr> <tr> <td>FU EORTC physical functioning</td> </tr> <tr> <td>FU EORTC role functioning</td> </tr> <tr> <td>FU EORTC emotional functioning</td> </tr> <tr> <td>FU EORTC cognitive functioning</td> </tr> <tr> <td>FU EORTC social functioning</td> </tr> <tr> <td>FU EORTC fatigue</td> </tr> <tr> <td>FU EORTC NV</td> </tr> <tr> <td>FU EORTC PA</td> </tr> <tr> <td>FU EORTC DY</td> </tr> <tr> <td>FU EORTC SL</td> </tr> <tr> <td>FU EORTC AP</td> </tr> <tr> <td>FU EORTC CO</td> </tr> <tr> <td>FU EORTC DI</td> </tr> <tr> <td>FU EORTC FI</td> </tr> <tr> <td>FU BN20 BNFU</td> </tr> <tr> <td>FU BN20 BNVD</td> </tr> <tr> <td>FU BN20 BNMD</td> </tr> <tr> <td>FU BN20 BNCD</td> </tr> <tr> <td>FU BN20 BNHA</td> </tr> <tr> <td>FU BN20 BNSE</td> </tr> <tr> <td>FU BN20 BNDR</td> </tr> <tr> <td>FU BN20 BNIS</td> </tr> <tr> <td>FU BN20 BNHL</td> </tr> <tr> <td>FU BN20 BNWL</td> </tr> <tr> <td>FU BN20 BNBC</td> </tr> <tr> <td>FU FAS raw score</td> </tr> <tr> <td>FU FAS standard score</td> </tr> <tr> <td>FU FAS equivalent score</td> </tr> <tr> <td>FU ROWl IR raw score</td> </tr> <tr> <td>FU ROWL IR standard score</td> </tr> <tr> <td>FU ROWL IR equivalent score</td> </tr> <tr> <td>FU ROWL DR raw score</td> </tr> <tr> <td>FU ROWL DR standard score</td> </tr> <tr> <td>FU ROWL DR equivalent score</td> </tr> <tr> <td>FU TMTA raw score</td> </tr> <tr> <td>FU TMTA standard score</td> </tr> <tr> <td>FU TMTA equivalent score</td> </tr> <tr> <td>FU TMTB raw score</td> </tr> <tr> <td>FU TMTB standard score</td> </tr> <tr> <td>FU TMTB equivalent score</td> </tr> <tr> <td>FU TMTBA PG</td> </tr> <tr> <td>FU TMTBA PC</td> </tr> <tr> <td>FU TMTBA PE</td> </tr> <tr> <td>FU MOCATOT raw score</td> </tr> <tr> <td>FU MOCATOT standard score</td> </tr> <tr> <td>FU MOCATOT equivalent score</td> </tr> <tr> <td>FU MOCAVisuospatial PG</td> </tr> <tr> <td>FU MOCAExecutive PG</td> </tr> <tr> <td>FU MOCALanguage PG</td> </tr> <tr> <td>FU MOCAOrientation PG</td> </tr> <tr> <td>FU MOCAAttention PG</td> </tr> <tr> <td>FU MOCAMemory PG</td> </tr> <tr> <td>FU MOCAVisuospatial PC</td> </tr> <tr> <td>FU MOCAExecutive PC</td> </tr> <tr> <td>FU MOCALanguage PC</td> </tr> <tr> <td>FU MOCAOrientation PC</td> </tr> <tr> <td>FU MOCAAttention PC</td> </tr> <tr> <td>FU MOCAMemory PC</td> </tr> <tr> <td>FU MOCAVisuospatial PC A</td> </tr> <tr> <td>FU MOCAExecutive PE</td> </tr> <tr> <td>FU MOCALanguage PE</td> </tr> <tr> <td>FU MOCAOrientation PE</td> </tr> <tr> <td>FU MOCAAttention PE</td> </tr> <tr> <td>FU MOCAMemory PE</td> </tr> <tr> <td>GliomaEMeningioma</td> </tr> <tr> <td>employment status</td> </tr> <tr> <td>DeltaKPS</td> </tr> </tbody> </table> <p> </p>
Dataset related to article "Radiosurgery of limited brain metastases from primary solid tumor: results of the randomized phase III trial (NCT02355613) comparing treatments executed with a specialized or a C-arm linac-based platform"
<p>This record contains raw data related to article "Radiosurgery of limited brain metastases from primary solid tumor: results of the randomized phase III trial (NCT02355613) comparing treatments executed with a specialized or a C-arm linac-based platform"</p><p>Abstract</p><p>Background: Comparative prospective data regarding different radiosurgery (SRS) modalities for treating brain metastases (BMs) from solid tumors are not available. To investigate with a single institute phase III randomized trial whether SRS executed with linac (Arm-B) is superior to a dedicated multi-source gamma-ray stereotactic platform (Arm-A).</p><p>Methods: Adults patients with 1-4 BMs from solid tumors up to 30 mm in maximum diameter were randomly assigned to arms A and B. The primary endpoint was cumulative incidence of symptomatic (grade 2-3) radionecrosis (CIRN). Secondary endpoints were local progression cumulative incidence (CILP), distant brain failure, disease-free survival (DFS), and overall survival (OS).</p><p>Results: A total of 251 patients were randomly assigned to Arm-A (121) or Arm-B (130). The 1-year RN cumulative incidence was 6.7% in whole cohort, 3.8% (95% CI 1.9-7.4%) in Arm-B, and 9.3% (95% CI 6.2-13.8%) in the Arm-A (p = 0.43). CIRN was influenced by target volume irradiated only for the Arm-A (p << 0.001; HR 1.36 [95% CI 1.25-1.48]). Symptomatic RN occurred in 56 cases at a median time of 10.3 months (range 1.15-54.8 months), 27 in the Arm-B at a median time of 15.9 months (range 4.9-54.8 months), and 29 in the Arm-A at a median time of 6.9 months (1.2-32.3 months), without statistically significant differences between the two arms. No statistically significant differences were recorded between the two arms in CILP, BDF, DFS or OS. The mean beam-on time to deliver SRS was 49.0 ± 36.2 min in Arm-A, and 3.1 ± 1.6 min in Arm-B.</p><p>Conclusions: Given the technical differences between the treatment platforms investigated in this single-institution study, linac-based SRS (Arm-B) did not lead to significantly lower grade 2-3 RN rates versus the multi-source gamma-ray system (Arm-A) in a population of patients with limited brain metastases of small volume. No significant difference in local control was observed between both arms. For Arm-B, the treatment delivery time was significantly lower than for Arm-A.</p><p> </p><p>Trial registration: ClinicalTrials.gov Identifier NCT02355613.</p><p> </p>
Transcriptomic hallmarks of tumor plasticity and stromal interactions in brain metastasis
GEO Series GSE115702. Homo sapiens; Mus musculus. 48 samples. Type: Expression profiling by high throughput sequencing.
Sox9 directs divergent epigenomic states in brain tumor subtypes (ChIP-Seq)
GEO Series GSE202960. Mus musculus; Homo sapiens. 25 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.
Combining anti-PD1 and vorinostat improves anti-tumor treatment in IDH-mutant brain tumors
GEO Series GSE248513. Mus musculus. 15 samples. Type: Expression profiling by high throughput sequencing.
Gene expression analysis of murine 4T1 breast cancer cells derived from primary tumor, lung metastasis and brain metastasis
GEO Series GSE54773. Mus musculus. 9 samples. Type: Expression profiling by array.
Molecular Characterization across Pediatric Brain Tumors and Other Solid and Hematologic Malignancies for Research, Diagnostic, and Precision Medicine
Open the record for dataset details and reuse information.
Children's Brain Tumor Network
Namespace hosted on the Kids First DRC FHIR services at fhir.kidsfirstdrc.org
Patient and xenograft-derived organoids recapitulate brain tumor features and patient treatments
<p>scRNAseq data (G3 Medulloblastoma)</p>
Patient and xenograft-derived organoids recapitulate brain tumor features and patient treatments
<p>DNA methylation data 1</p>
Patient and xenograft-derived organoids recapitulate brain tumor features and patient treatments
<p>DNA methylation data PDXO</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.